Cuvposa

Cuvposa is a brand name of glycopyrrolate, approved by the FDA in the following formulation(s):

CUVPOSA (glycopyrrolate - solution; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approval date: July 28, 2010
  
  Strength(s): 1MG/5ML ^[RLD]

Has a generic version of Cuvposa been approved?

No. There is currently no therapeutically equivalent version of Cuvposa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cuvposa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of glycopyrrolate
  Patent 7,638,552
  Issued: December 29, 2009
  Inventor(s): Roberts; Alan & Venkataraman; Balaji
  Assignee(s): Sciele Pharma, Inc.
  The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of glycopyrrolate and a pharmaceutically acceptable carrier, prescribing information including advice regarding the administration of glycopyrrolate without food to improve bioavailability, and a container.
  
  Patent expiration dates:
  
  
  • August 20, 2023
    
    ✓ 
    Patent use: REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
  
  



• 
  Method for increasing the bioavailability of glycopyrrolate
  Patent 7,816,396
  Issued: October 19, 2010
  Inventor(s): Roberts; Alan & Venkataraman; Balaji
  Assignee(s): Shionogi Pharma, Inc.
  The invention relates to a method of treating sialorrhea in a human patient, which comprises orally administering glycopyrrolate in a liquid solution to the human patient under fasted conditions.
  
  Patent expiration dates:
  
  
  • August 20, 2023
    
    ✓ 
    Patent use: REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 28, 2013 - NEW PRODUCT
  
  

See also...

• Cuvposa Consumer Information (Drugs.com)
• Cuvposa Solution Consumer Information (Wolters Kluwer)
• Cuvposa Consumer Information (Cerner Multum)
• Cuvposa Advanced Consumer Information (Micromedex)
• Glycopyrrolate Consumer Information (Wolters Kluwer)
• Glycopyrrolate Solution Consumer Information (Wolters Kluwer)
• Glycopyrrolate Tablets Consumer Information (Wolters Kluwer)
• Glycopyrrolate Consumer Information (Cerner Multum)
• Glycopyrrolate Advanced Consumer Information (Micromedex)
• Glycopyrrolate AHFS DI Monographs (ASHP)